Clinical trials located in

Torrette

Torrette city is located in Italy. Currently, 8 clinical trials are being conducted in this city.

Torrette is a coastal locality in the Marche region of Italy, known for its affiliation with the city of Ancona. It stands out for its healthcare facilities, notably the presence of the regionally acclaimed Torrette Hospital, a hub for medical excellence. The area is characterized by its picturesque beaches, offering a serene Mediterranean landscape. Historically, Torrette has been a vital area for fishing, reflecting its deep-rooted connection with the sea. Its modern development includes a blend of residential areas and commercial growth, making it a unique blend of traditional and contemporary Italian life.

  • CT-EU-00041479

    Study on the efficacy of pirtobrutinib for mantle cell lymphoma

    This clinical trial is designed for patients diagnosed with mantle cell lymphoma (MCL), a type of blood cancer. The primary objective of the study is to assess the efficacy of a new drug called pirtobrutinib in comparison to other similar drugs that have received approval from the U.S. Food and Drug Administration (FDA). Participants may be involved in the study for a duration of two years or more, contingent on their condition not worsening. The trial will categorize patients into two groups: one receiving pirtobrutinib, and the other receiving either ibrutinib, acalabrutinib, or zanubrutinib, which are existing FDA-approved drugs for this condition. Throughout the study, the participants’ health condition, symptoms, and any side effects will be closely monitored. Additionally, the effectiveness of the treatments will be measured by evaluating the eventual survival rates of the patients.

    • Pirtobrutinib/LOXO-305
    • Zanubrutinib
    • Ibrutinib
    • Acalabrutinib
  • Study testing Ruxolitinib cream for Prurigo Nodularis treatment

    This study is testing a cream with Ruxolitinib to see if it’s safe and effective for people with a skin condition called Prurigo Nodularis (PN). The study has three main parts. In the first 12 weeks, participants will receive either the cream with Ruxolitinib or placebo (also known as vehicle-controlled) treatment. After that, all participants will receive the cream with Ruxolitinib for another 40 weeks. After that, there will be an extra 30 days to keep an eye on safety. The trial will measure success by checking if the cream can reduce itchiness. Treatment success will be evaluated by medical professionals, considering factors such as the number of skin nodules and the extent of redness and crusting in the condition’s severity.

    • Ruxolitinib
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Belimumab study for systemic sclerosis-lung disease

    This study evaluates belimumab’s efficacy and safety compared to a placebo in treating systemic sclerosis-associated interstitial lung disease (SSc-ILD). Approximately 300 participants will receive belimumab or a placebo alongside standard therapy. The main focus is on the drug’s impact on lung function, skin thickening, and symptoms affecting quality of life, like fatigue. The study aims to provide insights into better managing SSc-ILD, improving patient outcomes.

    • Belimumab
  • Comparing depemokimab and mepolizumab in eosinophilic granulomatosis with polyangiitis

    This clinical trial examines the effects of a depemokimab, compared to an existing one, mepolizumab, for adults facing a persistent lung and blood vessel condition known as eosinophilic granulomatosis with polyangiitis (EGPA). It explores which treatment is more effective and safer when used with standard therapy. About 160 adults who have had EGPA for at least six months will join this study. They will receive either depemokimab or mepolizumab alongside a placebo. The trial is blinded, meaning neither the participants nor the researchers will know who receives which treatment. Success is measured by the participants’ remission status and how long they stay symptom-free during the 52-week period.

    • Mepolizumab
    • Depemokimab
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in Italy:

.